A B-cell targeted TLR9 Agonist Antibody Conjugate Potentiates Cancer Vaccine Efficacy and Rejuvenates Vaccine Responses in the Elderly
Abstract #: 6746
PDF
INCLINE-101: Preliminary Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAC-001 (TLR9 Agonist Conjugated to a CD22 mAb) in Patients With Advanced or Metastatic Solid Tumors
Abstract #: 743
PDF
TAC-003, a TLR9 Agonist Antibody Conjugate for Targeted Immunotherapy of Nectin-4 Expressing Tumors
Abstract #: 1121
PDF
A Nectin-4 Targeted TLR9 Agonist Antibody Conjugate Induces Robust Immune Cell Activation and Anti-Tumor Responses
Abstract #: 1162
PDF
INCLINE-101, A Phase 1/2, Open Label, Dose Escalation and Expansion Study of TAC-001 (a TLR9 agonist conjugated to an anti-CD22 antibody) in Patients with Select Advanced or Metastatic Solid Tumors
PDF
ALTA-002, a SIRPα-Directed TLR9 Agonist Antibody Conjugate, Activates Myeloid Cells And Promotes Anti-Tumor Immunity
Abstract #: 780
PDF
TAC-001, a toll-like receptor 9 (TLR9) agonist antibody conjugate targeting B cells, promotes antitumor immunity and favorable safety profile following systemic administration in preclinical models
Abstract #: 1721
PDF
Targeted Immune Cell Activation by Systemic Delivery of Toll-Like Receptor 9 Agonist Antibody Conjugates Induce Potent Anti-Tumor Immunity
Abstract #: 615
PDF